Product Pipeline

Our current development pipeline consists of 3 lead molecules: LSF, DT 22669 and DT 23552. DT 22669 and DT 23552 are planned oral drugs. These three molecules are being applied to eight therapeutic indications.

Our first expected product is a component of the preparation process for islet cells before they are transplanted. That product is expected to launch in 2007.

This chart indicates the development stage of each potential DiaKine product.

	Discovery	Lead Molecule	Preclinical	Phase 1	Phase 2
	Parenteral Drugs: Type 1 Diabetes
Post islet cell transplant therapy	LSF, IV
Treatment newly diagnosed type 1	LSF, SC
	*Oral Drugs: LADA, Type 2 and Complications*
LADA	DT 22669
Insulin-dependent type 2	DT 22669
Diabetic nephropathy	DT 23552
Diabetic retinopathy	DT 23552
Diabetic cardio complications
Metabolic syndrome

DiaKine Therapeutics • 1414 Sachem Place • Suite 3 • Charlottesville, VA 22901 • 434-975-2001